An abstract on rod-derived cone viability factor (RdCVF) in pig models of Retinitis Pigmentosa (RP) has been accepted for a poster presentation at ASGCT 2021 Annual Meeting, to be held virtually on 11-14 May.
Paris, April 15, 2021 – SparingVision (the “Company”), a genomic medicines company developing vision saving treatments for ocular diseases, today announces that an abstract on rod-derived cone viability factor (RdCVF) in pig models of Retinitis Pigmentosa (RP) has been accepted for a poster presentation at ASGCT 2021 Annual Meeting, to be held virtually on 11-14 May (details and timing of the presentation below). The poster was developed in the laboratory of Dr. McCall of University of Louisville, Kentucky, SparingVision’s academic collaborators. SparingVision’s novel approach to treat RP and other rod-cone dystrophies, SPVN06, introduces rod-derived cone viability factors in order to prevent degeneration of photoreceptors in the retina.
Title: Rod-Derived Cone Viability Factor Provides Trophic Support for Cone Photoreceptors in a Pig Model of Retinitis Pigmentosa
Date and Time: Tuesday May 11th 2021, 8:00 AM – 10:00 AM EST
Presenter: Dr. Jennifer Noel, University of Louisville
Session Title: Neurologic Diseases
Abstract #: 552
The abstract will also be published on the ASGCT website from 4:30 PM EST on April 27th.
About SparingVision
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments.
Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause.
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible.
SparingVision has raised €60 million to date and its investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.